Annual EBITDA
$26.27 M
+$48.45 M+218.44%
December 31, 2023
Summary
- As of February 12, 2025, RDHL annual EBITDA is $26.27 million, with the most recent change of +$48.45 million (+218.44%) on December 31, 2023.
- During the last 3 years, RDHL annual EBITDA has risen by +$81.25 million (+147.79%).
- RDHL annual EBITDA is now at all-time high.
Performance
RDHL EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
N/A
June 1, 2024
Summary
- RDHL quarterly EBITDA is not available.
Performance
RDHL Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM EBITDA
N/A
June 1, 2024
Summary
- RDHL TTM EBITDA is not available.
Performance
RDHL TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
RDHL EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +218.4% | - | - |
| 3 y3 years | +147.8% | - | - |
| 5 y5 years | +167.8% | - | - |
RDHL EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +141.7% | ||||
| 5 y | 5-year | at high | +141.7% | ||||
| alltime | all time | at high | +141.7% |
RedHill Biopharma EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2023 | $26.27 M(-218.4%) | - | - |
| Jun 2023 | - | $2.69 M(-97.6%) | $111.71 M(+8.0%) |
| Mar 2023 | - | $111.15 M(<-9900.0%) | $103.45 M(-566.4%) |
| Dec 2022 | -$22.18 M(-64.8%) | -$294.00 K(-83.9%) | -$22.18 M(-29.5%) |
| Sep 2022 | - | -$1.83 M(-67.3%) | -$31.48 M(-29.6%) |
| Jun 2022 | - | -$5.58 M(-61.5%) | -$44.69 M(-27.6%) |
| Mar 2022 | - | -$14.48 M(+51.0%) | -$61.68 M(-2.1%) |
| Dec 2021 | -$63.03 M(+14.6%) | -$9.59 M(-36.3%) | -$62.99 M(-11.2%) |
| Sep 2021 | - | -$15.04 M(-33.4%) | -$70.94 M(+4.7%) |
| Jun 2021 | - | -$22.58 M(+43.0%) | -$67.74 M(+22.3%) |
| Mar 2021 | - | -$15.79 M(-10.0%) | -$55.37 M(+0.8%) |
| Dec 2020 | -$54.98 M(+35.1%) | -$17.54 M(+48.1%) | -$54.95 M(+13.3%) |
| Sep 2020 | - | -$11.84 M(+16.0%) | -$48.50 M(+5.3%) |
| Jun 2020 | - | -$10.20 M(-33.6%) | -$46.05 M(-0.9%) |
| Mar 2020 | - | -$15.38 M(+38.7%) | -$46.45 M(+17.1%) |
| Dec 2019 | -$40.70 M(+5.1%) | -$11.08 M(+18.1%) | -$39.69 M(+3.1%) |
| Sep 2019 | - | -$9.39 M(-11.5%) | -$38.48 M(-0.5%) |
| Jun 2019 | - | -$10.61 M(+23.2%) | -$38.67 M(+3.3%) |
| Mar 2019 | - | -$8.61 M(-12.8%) | -$37.44 M(-3.2%) |
| Dec 2018 | -$38.73 M(-14.8%) | -$9.87 M(+3.0%) | -$38.67 M(-1.5%) |
| Sep 2018 | - | -$9.58 M(+2.2%) | -$39.25 M(-9.7%) |
| Jun 2018 | - | -$9.38 M(-4.7%) | -$43.46 M(-3.6%) |
| Mar 2018 | - | -$9.84 M(-5.9%) | -$45.08 M(+3.0%) |
| Dec 2017 | -$45.46 M | -$10.46 M(-24.2%) | -$43.77 M(+2.2%) |
| Sep 2017 | - | -$13.79 M(+25.4%) | -$42.85 M(+14.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2017 | - | -$11.00 M(+28.9%) | -$37.39 M(+13.6%) |
| Mar 2017 | - | -$8.53 M(-10.5%) | -$32.91 M(+10.1%) |
| Dec 2016 | -$30.50 M(+38.8%) | -$9.53 M(+14.3%) | -$29.89 M(+6.7%) |
| Sep 2016 | - | -$8.33 M(+27.9%) | -$28.01 M(+22.6%) |
| Jun 2016 | - | -$6.52 M(+18.2%) | -$22.84 M(+3.6%) |
| Mar 2016 | - | -$5.51 M(-27.9%) | -$22.04 M(+5.0%) |
| Dec 2015 | -$21.97 M(+106.8%) | -$7.64 M(+141.7%) | -$20.98 M(+11.7%) |
| Sep 2015 | - | -$3.16 M(-44.7%) | -$18.78 M(-3.6%) |
| Jun 2015 | - | -$5.71 M(+28.1%) | -$19.48 M(+9.8%) |
| Mar 2015 | - | -$4.46 M(-18.1%) | -$17.74 M(+79.4%) |
| Dec 2014 | -$10.62 M(-1.2%) | -$5.44 M(+41.0%) | -$9.89 M(+23.1%) |
| Sep 2014 | - | -$3.86 M(-2.9%) | -$8.03 M(+17.0%) |
| Jun 2014 | - | -$3.98 M(-217.3%) | -$6.86 M(+27.3%) |
| Mar 2014 | - | $3.39 M(-194.5%) | -$5.39 M(-49.8%) |
| Dec 2013 | -$10.75 M(+19.2%) | -$3.59 M(+33.4%) | -$10.75 M(+14.2%) |
| Sep 2013 | - | -$2.69 M(+7.4%) | -$9.41 M(+9.6%) |
| Jun 2013 | - | -$2.50 M(+27.2%) | -$8.59 M(+5.9%) |
| Mar 2013 | - | -$1.97 M(-12.6%) | -$8.11 M(-7.9%) |
| Dec 2012 | -$9.02 M(+14.7%) | -$2.25 M(+20.7%) | -$8.81 M(-2.2%) |
| Sep 2012 | - | -$1.86 M(-7.8%) | -$9.01 M(-3.8%) |
| Jun 2012 | - | -$2.02 M(-24.2%) | -$9.36 M(+27.6%) |
| Mar 2012 | - | -$2.67 M(+8.8%) | -$7.34 M(+57.1%) |
| Dec 2011 | -$7.86 M(+353.4%) | -$2.45 M(+10.7%) | -$4.67 M(+110.7%) |
| Sep 2011 | - | -$2.22 M | -$2.22 M |
| Dec 2010 | -$1.73 M | - | - |
FAQ
- What is RedHill Biopharma annual EBITDA?
- What is the all time high annual EBITDA for RedHill Biopharma?
- What is RedHill Biopharma annual EBITDA year-on-year change?
- What is the all time high quarterly EBITDA for RedHill Biopharma?
- What is the all time high TTM EBITDA for RedHill Biopharma?
What is RedHill Biopharma annual EBITDA?
The current annual EBITDA of RDHL is $26.27 M
What is the all time high annual EBITDA for RedHill Biopharma?
RedHill Biopharma all-time high annual EBITDA is $26.27 M
What is RedHill Biopharma annual EBITDA year-on-year change?
Over the past year, RDHL annual EBITDA has changed by +$48.45 M (+218.44%)
What is the all time high quarterly EBITDA for RedHill Biopharma?
RedHill Biopharma all-time high quarterly EBITDA is $111.15 M
What is the all time high TTM EBITDA for RedHill Biopharma?
RedHill Biopharma all-time high TTM EBITDA is $111.71 M